Skip header and navigation

Refine By

213 records – page 1 of 22.

99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: immune therapies of type 1 diabetes: new opportunities based on the hygiene hypothesis.

https://arctichealth.org/en/permalink/ahliterature144028
Source
Clin Exp Immunol. 2010 Apr;160(1):106-12
Publication Type
Article
Date
Apr-2010
Author
L. Chatenoud
S. You
H. Okada
C. Kuhn
B. Michaud
J-F Bach
Author Affiliation
Université Paris Descarte, Paris, France. lucienne.chatenoud@inserm.fr
Source
Clin Exp Immunol. 2010 Apr;160(1):106-12
Date
Apr-2010
Language
English
Publication Type
Article
Keywords
Adolescent
Animals
Autoantigens - immunology
Bacteria - immunology
Canada - epidemiology
Child
Diabetes Mellitus, Type 1 - immunology - therapy
Europe - epidemiology
Humans
Hygiene
Hypersensitivity - immunology
Immunosuppression - methods
Immunotherapy - methods
Infection - immunology - microbiology
Mice
Pancreatitis - immunology - microbiology
Toll-Like Receptors - agonists
Young Adult
Abstract
Insulin-dependent (type 1) diabetes is a prototypic organ-specific autoimmune disease resulting from the selective destruction of insulin-secreting beta cells within pancreatic islets of Langerhans by an immune-mediated inflammation involving autoreactive CD4(+) and CD8(+) T lymphocytes which infiltrate pancreatic islets. Current treatment is substitutive, i.e. chronic use of exogenous insulin which, in spite of significant advances, is still associated with major constraints (multiple daily injections, risks of hypoglycaemia) and lack of effectiveness over the long term in preventing severe degenerative complications. Finding a cure for autoimmune diabetes by establishing effective immune-based therapies is a real medical health challenge, as the disease incidence increases steadily in industrialized countries. As the disease affects mainly children and young adults, any candidate immune therapy must therefore be safe and avoid a sustained depression of immune responses with the attendant problems of recurrent infection and drug toxicity. Thus, inducing or restoring immune tolerance to target autoantigens, controlling the pathogenic response while preserving the host reactivity to exogenous/unrelated antigens, appears to be the ideal approach. Our objective is to review the major progress accomplished over the last 20 years towards that aim. In addition, we would like to present another interesting possibility to access new preventive strategies based on the 'hygiene hypothesis', which proposes a causal link between the increasing incidence of autoimmune diseases, including diabetes, and the decrease of the infectious burden. The underlying rationale is to identify microbial-derived compounds mediating the protective activity of infections which could be developed therapeutically.
Notes
Cites: J Immunol. 2000 Jun 1;164(11):5683-810820244
Cites: Clin Exp Immunol. 2010 Apr;160(1):1-920415844
Cites: Lancet. 2000 Aug 12;356(9229):545-910950231
Cites: Diabetologia. 2000 Aug;43(8):1000-410990077
Cites: J Immunol. 2000 Dec 1;165(11):6148-5511086048
Cites: Annu Rev Immunol. 2001;19:131-6111244033
Cites: J Immunol. 2001 Jul 15;167(2):1081-911441119
Cites: Lancet. 2001 Nov 24;358(9295):1749-5311734230
Cites: Nature. 2002 Apr 11;416(6881):603-711948342
Cites: Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5539-4411943868
Cites: N Engl J Med. 2002 May 30;346(22):1685-9112037147
Cites: N Engl J Med. 2002 May 30;346(22):1740-212037155
Cites: N Engl J Med. 2002 Sep 19;347(12):911-2012239261
Cites: Vaccine. 2003 Feb 14;21(9-10):836-4212547591
Cites: Int Immunopharmacol. 2003 Mar;3(3):417-2512639819
Cites: Science. 1984 Mar 30;223(4643):1362-76367043
Cites: Lancet. 1986 Jul 19;2(8499):119-242873396
Cites: Diabetes. 1986 Aug;35(8):855-603525284
Cites: J Exp Med. 1989 May 1;169(5):1669-802523954
Cites: BMJ. 1989 Nov 18;299(6710):1259-602513902
Cites: J Autoimmun. 1989 Dec;2(6):759-762533502
Cites: Chem Pharm Bull (Tokyo). 1992 Apr;40(4):1004-61525928
Cites: Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):123-78278351
Cites: Endocr Rev. 1994 Aug;15(4):516-427988484
Cites: Diabetes Metab. 1996 Oct;22(5):341-88896996
Cites: J Exp Med. 1996 Nov 1;184(5):2049-538920894
Cites: J Immunol. 1997 Mar 15;158(6):2947-549058834
Cites: Immunology. 1962 May;5:378-8813887798
Cites: Nat Med. 2005 Feb;11(2):138-4515654326
Cites: N Engl J Med. 2005 Jun 23;352(25):2598-60815972866
Cites: J Exp Med. 2005 Oct 17;202(8):1131-916230478
Cites: J Exp Med. 2005 Nov 7;202(9):1171-716260486
Cites: Diabetes. 2006 Jan;55(1):179-8516380491
Cites: J Neuroimmunol. 2006 Mar;172(1-2):94-10316360885
Cites: Immunol Rev. 2006 Aug;212:185-20216903915
Cites: J Med Chem. 2006 Oct 5;49(20):6000-1417004714
Cites: Immunobiology. 2006;211(10):767-7717113914
Cites: Nat Rev Immunol. 2007 May;7(5):353-6417457343
Cites: Pediatr Diabetes. 2007 Oct;8 Suppl 6:6-1417727380
Cites: J Clin Invest. 2007 Dec;117(12):3857-6718060033
Cites: N Engl J Med. 2008 Feb 14;358(7):676-8818272891
Cites: J Immunol. 2008 Mar 1;180(5):2863-7518292508
Cites: Lancet. 2008 May 24;371(9626):1777-8218502302
Cites: N Engl J Med. 2008 Oct 30;359(18):1909-2018843118
Cites: Lancet. 2008 Nov 15;372(9651):1746-5518814906
Cites: Nat Rev Endocrinol. 2009 Apr;5(4):219-2619352320
Cites: Lancet. 2009 Jun 13;373(9680):2027-3319481249
Cites: Diabetes Care. 2009 Nov;32(11):2036-4019690081
Cites: N Engl J Med. 2009 Nov 26;361(22):2143-5219940299
Cites: Eur J Biochem. 2000 Jun;267(11):3370-710824125
PubMed ID
20415859 View in PubMed
Less detail
Source
Tidsskr Nor Laegeforen. 1996 Feb 10;116(4):471
Publication Type
Article
Date
Feb-10-1996

Alcohol advertising bans and alcohol abuse: an international perspective.

https://arctichealth.org/en/permalink/ahliterature226519
Source
J Health Econ. 1991 May;10(1):65-79
Publication Type
Article
Date
May-1991
Author
H. Saffer
Author Affiliation
National Bureau of Economic Research, New York University, NY 10003.
Source
J Health Econ. 1991 May;10(1):65-79
Date
May-1991
Language
English
Publication Type
Article
Keywords
Accidents, Traffic - statistics & numerical data
Advertising as Topic - legislation & jurisprudence
Alcohol Drinking - legislation & jurisprudence
Alcoholic Beverages - utilization
Canada - epidemiology
Cross-Sectional Studies
Europe - epidemiology
Health Behavior
Humans
Liver Cirrhosis - mortality
Models, Statistical
Public Policy
United States - epidemiology
World Health
Abstract
This paper examines the effect of banning broadcast advertising of alcoholic beverages. The data used in this study are a pooled time series from 17 countries for the period 1970 to 1983. The empirical results show that countries with bans on spirits advertising have about 16% lower alcohol consumption than countries with no bans and that countries with bans on beer and wine advertising have about 11% lower alcohol consumption than countries with bans only on spirits advertising.
Notes
Comment In: J Health Econ. 1993 Jul;12(2):213-2810127781
PubMed ID
10112150 View in PubMed
Less detail

Alcohol and pancreatitis mortality at the population level: experiences from 14 western countries.

https://arctichealth.org/en/permalink/ahliterature9394
Source
Addiction. 2004 Oct;99(10):1255-61
Publication Type
Article
Date
Oct-2004
Author
Mats Ramstedt
Author Affiliation
Centre for Social Research on Alcohol and Drugs, Stockholm University, Sweden. mats.ramstedt@sorad.su.se
Source
Addiction. 2004 Oct;99(10):1255-61
Date
Oct-2004
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Canada - epidemiology
Cross-Cultural Comparison
Data Collection - methods
Europe - epidemiology
Female
Humans
Male
Middle Aged
Pancreatitis, Alcoholic - mortality
Research Support, Non-U.S. Gov't
Abstract
AIMS: To test if there is relationship between alcohol consumption and pancreatitis mortality at the population level. DATA AND METHODS: Annual pancreatitis death rates for 1950-95 were converted into age-adjusted mortality rates per 100,000 inhabitants. Per capita alcohol consumption was measured by alcohol sales. The relationship was estimated with time-series analysis on data from 14 western countries. Several models were tested with different assumptions about risk function and lag structure. RESULTS: According to the assumed most appropriate model, a positive relationship was found in each country, and statistical significance was reached in all countries except from Finland, Italy and Canada. The magnitude of the association was fairly consistent across countries, with the alcohol effect parameters ranging between 0.05 and 0.14. However, Sweden and Norway deviated from this pattern with estimates between 0.30 and 0.40. CONCLUSIONS: Pancreatitis joins a wide range of causes of death where the mortality rate is influenced by per capita alcohol consumption, and more so in northern Europe. It is suggested that pancreatitis mortality is an important indicator of alcohol-related harm, not least because a large amount of morbidity is likely to be connected to the mortality rate.
Notes
Comment In: Addiction. 2004 Oct;99(10):1231-215369553
PubMed ID
15369563 View in PubMed
Less detail

[Alcohol, breast cancer and causal inference in epidemiology]

https://arctichealth.org/en/permalink/ahliterature10956
Source
Tidsskr Nor Laegeforen. 1997 Oct 30;117(26):3771-6
Publication Type
Article
Date
Oct-30-1997
Author
K. Kjaerheim
Author Affiliation
Institutt for epidemiologisk kreftforskning, Oslo.
Source
Tidsskr Nor Laegeforen. 1997 Oct 30;117(26):3771-6
Date
Oct-30-1997
Language
Norwegian
Publication Type
Article
Keywords
Alcohol Drinking - adverse effects
Breast Neoplasms - epidemiology - etiology
Canada - epidemiology
Causality
Clinical Trials
English Abstract
Europe - epidemiology
Female
Humans
Meta-Analysis
United States - epidemiology
Abstract
In order to demonstrate how possible causal relationships are critically evaluated in epidemiologic research, literature on the association between alcohol and breast cancer is reviewed and discussed. A cause can be defined as a factor which, in combination with other factors, known and unknown, is sufficient to produce an effect. Since the hypothesis-generating study was published in 1977, a total of 34 positive and 16 negative studies have been published. Methodological problems, such as chance, bias and confounding, cannot be considered as plausible explanations for the above majority of positive findings. The question of causality was then evaluated using the guidelines developed by Bradford Hill in 1965. Among these, the strength of the association, consistency, temporality, biological gradient and biological plausibility, are the most important. In spite of the relatively weak association and somewhat inconsistent results, it is concluded that alcohol consumption should be considered as a cause of breast cancer. It is estimated that in Norway, between 24 and 180 cases of breast cancer may be attributed to alcohol consumption. Future research should focus on the question of effect-modification and on the possible implications of different patterns of alcohol consumption.
PubMed ID
9417679 View in PubMed
Less detail

Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction.

https://arctichealth.org/en/permalink/ahliterature176663
Source
Am J Cardiol. 2005 Jan 15;95(2):228-33
Publication Type
Article
Date
Jan-15-2005
Author
Amir Kashani
C Michael Gibson
Sabina A Murphy
Marc S Sabatine
David A Morrow
Elliott M Antman
Robert P Giugliano
Author Affiliation
Rochester General Hospital, Rochester, New York, USA.
Source
Am J Cardiol. 2005 Jan 15;95(2):228-33
Date
Jan-15-2005
Language
English
Publication Type
Article
Keywords
Aged
Canada - epidemiology
Coronary Angiography - utilization
Europe - epidemiology
Female
Heart Failure - epidemiology - etiology - mortality - surgery
Humans
Male
Myocardial Infarction - complications - drug therapy
Myocardial Revascularization - utilization
Outcome Assessment (Health Care)
Plasminogen Activators - administration & dosage
Survival Analysis
Thrombolytic Therapy
United States - epidemiology
Abstract
We evaluated the use of coronary angiography and clinical outcomes among patients who had heart failure and were enrolled in the Intravenous Novel Plasminogen Activator (NPA) for the Treatment of Infarcting Myocardium Early study, a large international trial of fibrinolytic therapy in ST-elevation myocardial infarction.
PubMed ID
15642555 View in PubMed
Less detail

An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project.

https://arctichealth.org/en/permalink/ahliterature71472
Source
J Antimicrob Chemother. 2003 Jan;51(1):69-76
Publication Type
Article
Date
Jan-2003
Author
G. Kahlmeter
Author Affiliation
Department of Clinical Microbiology, Central Hospital, SE-351 85 Växjö, Sweden. gunnar.kahlmmeter@ltkronoberg.se
Source
J Antimicrob Chemother. 2003 Jan;51(1):69-76
Date
Jan-2003
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Anti-Bacterial Agents - pharmacology - therapeutic use
Canada - epidemiology
Community-Acquired Infections - drug therapy - epidemiology - microbiology
Drug Resistance, Bacterial - physiology
Enterobacteriaceae - drug effects - isolation & purification
Europe - epidemiology
Female
Health Surveys
Humans
Internationality
Middle Aged
Prevalence
Research Support, Non-U.S. Gov't
Urinary Tract Infections - drug therapy - epidemiology - microbiology
Abstract
The ECO.SENS study is the first international survey to investigate the prevalence and susceptibility of pathogens causing community-acquired acute uncomplicated urinary tract infections (UTIs). Midstream urine samples were taken for culture and for testing for the presence of leucocytes from 4734 women not older than 65 years presenting with symptoms of acute UTI at 252 community health care centres in 17 countries. Recognized urinary tract pathogens were identified and the susceptibility to 12 antimicrobials determined. Pathogens were present in 3278 (69.2%) patients, Escherichia coli accounting for 77.0% of isolates. In E. coli, 42% of the isolates were resistant to one or more of the 12 antimicrobial drugs investigated. Resistance was most common to ampicillin (29.8%) and sulfamethoxazole (29.1%), followed by trimethoprim (14.8%), trimethoprim/sulfamethoxazole (14.1%) and nalidixic acid (5.4%). Resistance in E. coli to co-amoxiclav, mecillinam, cefadroxil, nitrofurantoin, fosfomycin, gentamicin and ciprofloxacin was
PubMed ID
12493789 View in PubMed
Less detail

Annals of conflicting results: looking back on electromagnetic field research.

https://arctichealth.org/en/permalink/ahliterature210567
Source
CMAJ. 1996 Nov 15;155(10):1443-6
Publication Type
Article
Date
Nov-15-1996
Author
D. Schoen
Source
CMAJ. 1996 Nov 15;155(10):1443-6
Date
Nov-15-1996
Language
English
Publication Type
Article
Keywords
Canada - epidemiology
Child
Electromagnetic fields - adverse effects
Europe - epidemiology
Humans
Neoplasms - epidemiology - etiology
Occupational Diseases - epidemiology - etiology
Research Design
Risk
United States - epidemiology
Abstract
Few environmental health issues are as contentious as the question of whether exposure to electromagnetic fields (EMFs) from power lines increases cancer risk. Among the many actors in this controversy, epidemiologists have played the leading role in raising the question and motivating research. Epidemiologic studies of the effects of exposure to power-line EMFs include the investigation by Dr. Gilles Thériault and colleagues into incidence rates of cancer among electric-utility workers in Quebec, Ontario and France. With the development of personal dosimeters to measure exposure to electric, magnetic and pulsed EMFs, occupational studies in the 1990s have made an important methodologic advance. But, as Thériault explains, improvements in assessing exposure have not yet translated into clear and consistent findings.
Notes
Cites: Am J Epidemiol. 1988 Jul;128(1):21-383164167
Cites: Bioelectromagnetics. 1990;11(2):159-672242051
Cites: Am J Epidemiol. 1991 Nov 1;134(9):923-371843457
Cites: Experientia. 1986 Feb 15;42(2):185-63948973
Cites: Am J Epidemiol. 1996 Jul 15;144(2):150-608678046
Cites: Am J Epidemiol. 1995 Jan 15;141(2):123-347817968
Cites: Am J Epidemiol. 1980 Mar;111(3):292-67361752
Cites: Brain Res Bull. 1993;30(1-2):153-68420625
Cites: Am J Epidemiol. 1994 Nov 1;140(9):805-207977291
Cites: Am J Epidemiol. 1994 Mar 15;139(6):550-728172168
Cites: Epidemiology. 1993 Mar;4(2):104-148452898
Cites: J Cell Biochem. 1993 Apr;51(4):381-68496241
Cites: J Cell Biochem. 1993 Apr;51(4):387-938496242
Cites: J Cell Biochem. 1993 Apr;51(4):394-4038098713
Cites: Am J Epidemiol. 1993 Oct 1;138(7):467-818213751
Cites: Cancer Causes Control. 1993 Sep;4(5):465-768218879
PubMed ID
8943934 View in PubMed
Less detail

Antiplatelet therapy following drug-eluting stent implantation: new clinical data and recommendations.

https://arctichealth.org/en/permalink/ahliterature157572
Source
Minerva Cardioangiol. 2008 Feb;56(1):139-54
Publication Type
Article
Date
Feb-2008
Author
J M Paradis
G. Ducrocq
J F Tanguay
Author Affiliation
University of Montreal, Montreal, Montreal Heart Institute, Faculty of Medicine, Montreal, Québec, Canada.
Source
Minerva Cardioangiol. 2008 Feb;56(1):139-54
Date
Feb-2008
Language
English
Publication Type
Article
Keywords
Canada - epidemiology
Coronary Artery Disease - therapy
Coronary Restenosis - prevention & control
Coronary Thrombosis - diagnosis - epidemiology - physiopathology - prevention & control
Drug-Eluting Stents - adverse effects
Europe - epidemiology
Humans
Italy - epidemiology
Platelet Aggregation Inhibitors - therapeutic use
Practice Guidelines as Topic
Prevalence
Randomized Controlled Trials as Topic
Risk assessment
Risk factors
Treatment Outcome
United States - epidemiology
Abstract
Technological developments in percutaneous coronary interventions (PCI) allow the possibility for less invasive revascularization in an increasing number of patients with atherosclerotic coronary artery disease. Bare-metal stents (BMS) have considerably improved the efficacy of PCI in addition to greatly reducing restenosis. However, even with standard stents, restenosis has remained a significant limitation of this revascularization technique. The advent of drug-eluting stents (DES) has dramatically reduced in-stent restenosis and, as a result, the need for repeat revascularization. However, their potential thrombogenicity has raised concerns about their clinical utility and long-term safety. Indeed, there is a possible higher rate of late stent thrombosis (LST) with DES compared with BMS. Antiplatelet therapy has been shown to be efficient in preventing DES thrombosis. Nevertheless, in the future, significant improvement will occur to improve the safety and efficacy of this therapy. This article will summarize the pathophysiology and the epidemiology of stent thrombosis (ST). Definitions of definite, probable and possible ST will be described. Furthermore, clinical risk factors for ST will be clearly enumerated. Then, the various antiplatelet therapeutic strategies used to prevent ST will be taken in consideration. Finally, a summary of the major recommendations about antiplatelet therapy made by some of the most prestigious learned societies will be presented.
PubMed ID
18432176 View in PubMed
Less detail

213 records – page 1 of 22.